PFS of patients with FL based on the time point of bendamustine use before axi-cel infusion. Kaplan-Meier estimates of PFS among enrolled patients with FL by investigator assessment in those who had no prior bendamustine exposure, received bendamustine within 6 months of leukapheresis, received bendamustine between 6 and 12 months of leukapheresis, and received bendamustine >12 months before leukapheresis.